Position in ARGX
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$82,117,850
New position
Shares Held
88,511
first reported quarter
Ownership
0.142%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#46
of 505 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Capital Research Global Investors holds $14,161,458,348 across 17 Biotechnology names. ARGX ranks #10 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
19,490,637 | $9,681,584,117 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
9,750,699 | $2,935,252,919 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
3,504,387 | $200,521,024 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
5,344,701 | $199,197,006 | |
| 5 | TECH |
BIO-TECHNE Corp
|
2,621,890 | $185,236,528 | |
| 6 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
1,532,303 | $170,131,602 | |
| 7 | KYMR |
Kymera Therapeutics, Inc.
|
1,388,881 | $159,262,984 | |
| 8 | CYTK |
Cytokinetics Inc
|
1,686,625 | $143,683,583 |
All Filings in ARGX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $82,117,850 | 88,511 | Shares | Defined | 2026-08-12 | |
| No filing history on record for this holder in this stock. | ||||||